Joseph Catanzaro
Stock Analyst at Piper Sandler
(1.18)
# 3,404
Out of 4,760 analysts
102
Total ratings
33.33%
Success rate
-16.05%
Average return
Main Sectors:
Stocks Rated by Joseph Catanzaro
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| IOVA Iovance Biotherapeutics | Maintains: Neutral | $7.5 → $6 | $3.73 | +60.86% | 10 | Feb 28, 2025 | |
| SDGR Schrödinger | Maintains: Overweight | $50 → $45 | $19.96 | +125.45% | 3 | Feb 27, 2025 | |
| MRUS Merus | Initiates: Overweight | $84 | $46.75 | +79.68% | 1 | Feb 13, 2025 | |
| GILD Gilead Sciences | Maintains: Overweight | $105 → $110 | $117.21 | -6.15% | 5 | Feb 12, 2025 | |
| EXEL Exelixis | Maintains: Overweight | $37 → $38 | $39.16 | -2.95% | 4 | Feb 12, 2025 | |
| KROS Keros Therapeutics | Maintains: Overweight | $40 → $15 | $10.92 | +37.43% | 3 | Jan 17, 2025 | |
| HALO Halozyme Therapeutics | Maintains: Neutral | $52 → $53 | $61.44 | -13.74% | 9 | Jan 10, 2025 | |
| CRDF Cardiff Oncology | Maintains: Overweight | $7 → $10 | $3.84 | +160.42% | 4 | Dec 13, 2024 | |
| RVMD Revolution Medicines | Maintains: Overweight | $57 → $70 | $36.82 | +90.11% | 2 | Nov 7, 2024 | |
| EPIX ESSA Pharma | Downgrades: Neutral | $15 → $2 | $1.62 | +23.46% | 2 | Nov 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $10 → $19 | $2.51 | +658.48% | 5 | Oct 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $19 | $4.50 | +322.22% | 1 | Oct 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $12 → $15 | $1.71 | +777.19% | 3 | Sep 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $5 → $1.75 | $1.93 | -9.33% | 3 | Aug 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $20 → $3.75 | $0.36 | +942.54% | 2 | Aug 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $6 → $4.75 | $2.91 | +63.23% | 4 | Aug 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $36 | $22.58 | +59.43% | 2 | Aug 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $40 | $8.07 | +395.66% | 5 | Jul 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $15 | $7.65 | +96.08% | 4 | Jun 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $35 | $13.59 | +157.54% | 1 | Jun 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $2.25 → $3.5 | $0.67 | +422.62% | 3 | May 28, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $4.5 | $0.76 | +488.62% | 1 | May 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $26 → $30 | $5.29 | +467.11% | 2 | Apr 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $20 | $1.63 | +1,126.99% | 1 | Apr 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $8 → $2 | $1.39 | +44.40% | 3 | Apr 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $15 → $10 | $0.81 | +1,131.53% | 4 | Mar 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $18 | $1.86 | +867.74% | 1 | Feb 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $30 → $25 | $1.14 | +2,092.98% | 3 | Oct 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $15 → $1.75 | $1.86 | -5.91% | 2 | May 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $18 → $20 | $20.67 | -3.24% | 1 | Dec 20, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $25 → $1.5 | $0.80 | +86.89% | 1 | May 5, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $12 → $10 | $0.43 | +2,247.42% | 2 | Mar 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $35 | $4.75 | +636.84% | 1 | Jun 21, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $60 | $1.53 | +3,821.57% | 1 | Mar 25, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $28 → $18 | $3.20 | +462.50% | 3 | Apr 7, 2020 |
Iovance Biotherapeutics
Feb 28, 2025
Maintains: Neutral
Price Target: $7.5 → $6
Current: $3.73
Upside: +60.86%
Schrödinger
Feb 27, 2025
Maintains: Overweight
Price Target: $50 → $45
Current: $19.96
Upside: +125.45%
Merus
Feb 13, 2025
Initiates: Overweight
Price Target: $84
Current: $46.75
Upside: +79.68%
Gilead Sciences
Feb 12, 2025
Maintains: Overweight
Price Target: $105 → $110
Current: $117.21
Upside: -6.15%
Exelixis
Feb 12, 2025
Maintains: Overweight
Price Target: $37 → $38
Current: $39.16
Upside: -2.95%
Keros Therapeutics
Jan 17, 2025
Maintains: Overweight
Price Target: $40 → $15
Current: $10.92
Upside: +37.43%
Halozyme Therapeutics
Jan 10, 2025
Maintains: Neutral
Price Target: $52 → $53
Current: $61.44
Upside: -13.74%
Cardiff Oncology
Dec 13, 2024
Maintains: Overweight
Price Target: $7 → $10
Current: $3.84
Upside: +160.42%
Revolution Medicines
Nov 7, 2024
Maintains: Overweight
Price Target: $57 → $70
Current: $36.82
Upside: +90.11%
ESSA Pharma
Nov 4, 2024
Downgrades: Neutral
Price Target: $15 → $2
Current: $1.62
Upside: +23.46%
Oct 31, 2024
Maintains: Overweight
Price Target: $10 → $19
Current: $2.51
Upside: +658.48%
Oct 7, 2024
Initiates: Overweight
Price Target: $19
Current: $4.50
Upside: +322.22%
Sep 23, 2024
Maintains: Overweight
Price Target: $12 → $15
Current: $1.71
Upside: +777.19%
Aug 27, 2024
Downgrades: Neutral
Price Target: $5 → $1.75
Current: $1.93
Upside: -9.33%
Aug 19, 2024
Maintains: Overweight
Price Target: $20 → $3.75
Current: $0.36
Upside: +942.54%
Aug 19, 2024
Maintains: Neutral
Price Target: $6 → $4.75
Current: $2.91
Upside: +63.23%
Aug 15, 2024
Maintains: Overweight
Price Target: $36
Current: $22.58
Upside: +59.43%
Jul 8, 2024
Maintains: Overweight
Price Target: $40
Current: $8.07
Upside: +395.66%
Jun 14, 2024
Maintains: Overweight
Price Target: $15
Current: $7.65
Upside: +96.08%
Jun 5, 2024
Maintains: Overweight
Price Target: $35
Current: $13.59
Upside: +157.54%
May 28, 2024
Upgrades: Overweight
Price Target: $2.25 → $3.5
Current: $0.67
Upside: +422.62%
May 16, 2024
Initiates: Overweight
Price Target: $4.5
Current: $0.76
Upside: +488.62%
Apr 25, 2024
Maintains: Overweight
Price Target: $26 → $30
Current: $5.29
Upside: +467.11%
Apr 22, 2024
Initiates: Overweight
Price Target: $20
Current: $1.63
Upside: +1,126.99%
Apr 5, 2024
Downgrades: Neutral
Price Target: $8 → $2
Current: $1.39
Upside: +44.40%
Mar 18, 2024
Maintains: Overweight
Price Target: $15 → $10
Current: $0.81
Upside: +1,131.53%
Feb 12, 2024
Initiates: Overweight
Price Target: $18
Current: $1.86
Upside: +867.74%
Oct 16, 2023
Maintains: Overweight
Price Target: $30 → $25
Current: $1.14
Upside: +2,092.98%
May 23, 2023
Downgrades: Neutral
Price Target: $15 → $1.75
Current: $1.86
Upside: -5.91%
Dec 20, 2022
Maintains: Overweight
Price Target: $18 → $20
Current: $20.67
Upside: -3.24%
May 5, 2022
Downgrades: Neutral
Price Target: $25 → $1.5
Current: $0.80
Upside: +86.89%
Mar 10, 2022
Maintains: Overweight
Price Target: $12 → $10
Current: $0.43
Upside: +2,247.42%
Jun 21, 2021
Initiates: Overweight
Price Target: $35
Current: $4.75
Upside: +636.84%
Mar 25, 2021
Initiates: Overweight
Price Target: $60
Current: $1.53
Upside: +3,821.57%
Apr 7, 2020
Maintains: Overweight
Price Target: $28 → $18
Current: $3.20
Upside: +462.50%